Supplementary tables.docx (54.25 kB)
Download file

Supplementary tables: Real-world association of HER2/ERBB2 concordance with trastuzumab clinical benefit in advanced esophagogastric cancer.docx

Download (54.25 kB)
dataset
posted on 31.08.2021, 10:18 by Stacey M. Stein, Jeremy Snider, Siraj M. Ali, Rebecca A. Miksad, Brian M. Alexander, Emily Castellanos, Alexa B. Schrock, Russell Madison, Akshay Swaminathan, Jeffrey M. Venstrom, Margaret McCusker

Supplementary table 1a: Versions of genomic sequencing and genes included (FoundationOne Version 1)

Supplementary table 1b: Versions of genomic sequencing and genes included (FoundationOne Version 2)

Supplementary table 1c: FoundationOne CDx (Version 3)

Supplemental table 2: Detailed patient selection criteria

Supplemental table 3: Patients with an unknown or indeterminate HER2 test results who met all other study inclusion criteria

Supplemental table 4: First line anti-HER2 therapy regimens in HER2+ patients stratified by ERBB2 amplification status

Supplemental table 5: Demographics and clinical characteristics of patients with HER2+ tumors who received first-line trastuzumab therapy

Supplemental table 6: Concurrent genomic alterations

Supplemental table 7: Distribution of ISH results for patients classified by IHC status (with positive ISH confirmation) (n = 59), by ERBB2 Amp

Supplemental table 8: Adjusted clinical outcomes for 1L trastuzumab in patients whose tumors were clinically HER2+, adjusting for IHC status (n=142)

Supplemental table 9: Adjusted clinical outcomes for 1L trastuzumab in patients by adjusting for KRAS status (n=142)

History